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SUMMARY
Melanomas accumulate a high burden of mutations that could potentially generate neoantigens, 
yet somehow suppress the immune response to facilitate continued growth. In this study, we 
identify a subset of human melanomas that have loss of function mutations in ATR, a kinase that 
recognizes and repairs UV-induced DNA damage and is required for cellular proliferation. ATR 
mutant tumors exhibit both the accumulation of multiple mutations and the altered expression of 
inflammatory genes, resulting in decreased T-cell recruitment and increased recruitment of 
macrophages known to spur tumor invasion. Taken together, these studies identify a mechanism by 
which melanoma cells modulate the immune microenvironment to promote continued growth.
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Tumors grow not only because they acquire mutations that promote their growth, but also because 
they prevent the immune system from recognizing them. Chen et al. identify ATR mutations in 
human melanoma tumors and determine that ATR mutant melanomas harness the immune system 
to accelerate tumor growth.
INTRODUCTION
Melanomas accumulate a high burden of UV-induced mutations (Hodis et al., 2012). While 
genomic studies have identified some putative melanoma driver mutations, leading to the 
development of agents such as MAP kinase inhibitors that induce tumor regression 
(Wellbrock and Arozarena, 2016), it is less understood how other UV-induced mutations and 
tumor heterogeneity as a whole modulates tumor growth. These questions are not easily 
addressed by existing in vivo models, as existing animal models are either genetically 
homogeneous or lack a functional immune system (Kuzu et al., 2015).
While UV-irradiation contributes to the high mutation burden in skin cancer (Martincorena 
et al., 2015), melanoma tumors accumulate even more mutations as they fail to repair UV-
damaged DNA. Patients with the DNA repair disorder Xeroderma Pigmentosum have an 
increased risk of melanoma (Masaki et al., 2014), while mutations that affect telomere 
maintenance are also linked to melanoma (Potrony et al., 2015), and mutations in CDKN2a, 
which is commonly defective in melanoma (Hayward, 2003), also regulates genome 
maintenance (Box and Terzian, 2008). Melanoma cells also have DNA damage checkpoint 
defects-70% of cutaneous melanoma cell lines demonstrate defective G1 checkpoint arrest 
(Carson et al., 2012). Finally, some patients predisposed to melanoma have mutations in the 
MC1R receptor which is known to activate DNA repair mechanisms (Cassidy et al., 2015) 
by modulating the activity of the ATR kinase (Jarrett et al., 2015; Jarrett et al., 2014).
The ATR kinase is essential for the viability of both human and mouse cells (Brown and 
Baltimore, 2000; Cortez et al., 2001). In response to single stranded DNA damage, the ATR 
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kinase is recruited to damaged DNA, becomes activated, and then phosphorylates its 
downstream target Chk1 (Cimprich and Cortez, 2008). Activation of Chk1 results in cell 
cycle arrest and DNA repair to prevent damaged cells from progressing through the cell 
cycle (Smits and Gillespie, 2015). Chk1 is essential for the development of murine 
melanocytes (Smith et al., 2013), identifying a specific role for ATR-Chk1 in the melanocyte 
lineage. While ATR is essential for replication, hypomorphic mutations in ATR are observed 
in Seckel syndrome (O’Driscoll et al., 2003), a recessive disorder characterized by 
developmental delay and premature aging. Similarly, ATR mutant (ATR mt) mice develop 
signs of premature aging and hair greying (Ruzankina et al., 2007). Partial loss-of-function 
ATR mutations also can cause an oropharyngeal cancer syndrome (Tanaka et al., 2012).
In this study, we sought to examine whether ATR mutations can contribute to the 
development of melanoma. We identify ATR loss of function mutations in human 
melanoma, and determine that introducing similar mutations into BRAF mt PTEN 
heterozygous mouse melanomas (Dankort et al., 2009) accelerates both tumor growth and 
mutation accumulation. ATR mt tumors in this model recruited proinflammatory 
macrophages while repelling T cells important for the anti-tumor response, identifying ATR 
mutations that modulate the immune response to promote growth.
RESULTS
Loss of Function ATR mutations are present in human melanoma
Initial studies identified mutations in the ATR pathway in human melanoma. 7% of 
melanoma tumors in the TCGA have mutations in genes that affect the ATR pathway (ATR 
and CHK1), with most of these mutations occurring in the ATR gene (6%) (Supplemental 
Data File1-sheet1). Analysis of an independent set of primary tumors revealed a higher 
incidence of ATR mutations (13%, Supplemental Data File1-sheet1). ATR mutations did not 
map to a specific hotspot within the open reading frame (Figure S1A, Supplemental Data 
File1-sheet2), and none of the ATR mutations observed were recurrent in the dataset 
analyzed. ATR mt tumor cell lines from this cohort were examined to determine whether 
they had defective cell cycle checkpoints. Upon UVB-irradiation, ATR is recruited to 
damaged DNA and initiates the phosphorylation of CHK1 at Serine 345, initiating cell cycle 
arrest (Marechal and Zou, 2013). While UVB-irradiation was sufficient to induce CHK1 
phosphorylation in ATR-WT melanomas (WM983B, A375, MNT1, WM3211, WM3428) 
(Figure1A, left panel and Figure S1B), it did not induce the accumulation of phospho-CHK1 
in ATR mt melanoma cell lines (JWCI-WGS18, JWCI-WGS22, MeWo, MB435S) as 
efficiently with the exception of JWCI-WGS01 and JWCI-WGS31 (Figure 1A).
To assess whether ATR mt melanoma cell lines had defective cell cycle checkpoints, we 
examined whether UVB-irradiation induced cell cycle arrest in ATR WT (WM983B, A375) 
or mt melanomas. We excluded MNT-1 cells from this analysis as melanin in these cells 
interfered with the EdU assay. ATR mt cell lines incorporated less EdU after 1 hr of labeling 
as compared to ATR WT cells (Figure 1B) whether or not they exhibited defects in Chk1 
phosphorylation, suggesting that all of these mts have some defects in the activation of ATR 
downstream targets. UVB-irradiation induced cell cycle arrest in ATR WT cells (A375), as 
similar percentages of EdU positive cells were observed in samples labeled for 1 hour 
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followed by a 6 hr post UV chase as was observed in control cells labeled for 1 hr (Figure 
1C, S1C). Several ATR-mt cell lines (JWCI-WGS18, MeWo, MB435S) had defects in UV-
induced cell cycle arrest, as cells were able to proliferate after UV-irradiation, diluting out 
the population of cells that were labeled with EdU during the first hour (Figure 1B, S1C). 
The ability to overcome this replication block (Figure 1C) correlated with the magnitude of 
defects in UVB-induced Chk1 phosphorylation (Figure 1A). Taken together, these studies 
verify that subsets of melanoma tumors have ATR loss of function mutations.
Next, we verified that the ATR mutants in MB435S, MeWo, and JWCI-WGS18 cell lines, 
which exhibited altered UVB-induced checkpoints, interfered with the function of WT ATR. 
ATR mt constructs were generated and expressed at low levels in an A375 melanoma cell 
line that also express WT ATR. Initial studies verified that each WT or mt Flag-tagged ATR 
construct was expressed at a low level in A375 cells, and that these cell lines expressed 
similar levels of total ATR (Figure 1D, left panel). While UVB-irradiation induced Chk1 
phosphorylation in cells that express WT ATR, UVB-irradiation was less efficient at 
inducing Chk1 phosphorylation in cells that express a kinase dead ATR mt (Figure 1D, 
D2475A) (Nghiem et al., 2001) or in cells that express the ATR mts that had defective DNA 
damage checkpoints as identified in Figure 1A and 1C (Figure 1D, right panel). These 
findings verify that the heterozygous ATR mutations observed in human tumors have 
functional consequences.
ATR mutations accelerate the growth and metastasis of melanomas in vivo
In order to determine whether ATR mutations contribute to tumor development and 
metastasis in vivo, we crossed Atrflox/flox mice in which the loxP sites flank the ATR kinase 
domain (Brown and Baltimore, 2003) (Figure 2A, 2B upper panel) with mice carrying a 
Tyrosinase::CreERT2 allele, a BrafCA allele, and zero, one or two copies of a Ptenlox4-5 allele 
(Dankort et al., 2009). The growth of nevi or tumors in this model could be modulated by 
altering the dosage of PTEN: melanocytes expressing mt BRAF and WT PTEN produce 
nevi but no melanoma, melanocytes expressing mt BRAF and one copy of PTEN form 
tumors that are visible after >75 days, while melanocytes that express mt BRAF and no 
PTEN rapidly develop melanomas that metastasize quickly (Dankort et al., 2009). Initial 
studies verified that: 1) mice containing BRAF mt melanocytes had a normal lifespan and 
didn’t develop tumors (Figure S2A); and 2) tumor development was influenced by the 
absence of one PTEN allele but not by ATR mt (Figure S2B).
In this set of experiments, we examined the consequences of ATR loss in nevi and 
melanoma using a published ATR flox model in which the excision of the ATR flox cassette 
is not 100% complete (Ruzankina et al., 2007), resulting in the generation of mice that have 
some melanocytes with no functional ATR and others with WT ATR. Over time, a mixed 
population of ATR−/− and ATR+/+ cells can then repopulate tissues of these animals. While 
this feature makes it difficult to measure the effect of complete ATR loss on tumor growth, it 
does generate tumors that have a mixture of different mutations as is observed in human 
melanoma. Induction of recombination with topical 4-OHT in these mice would result in the 
simultaneous BRAFV600E mutation, generation of some cells with mixed deletion of the 
ATR kinase domain (termed ATRmD), and PTEN deletion specifically in melanocytes 
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(Figure 2A). The ATR protein is very large (300 kDa), yet the kinase domain of the protein 
is very small, making it impossible to distinguish truncated ATR from full length ATR by 
western blotting (Figure S2C). RT-PCR (reverse transcriptase PCR) of tumor RNA 
successfully demonstrated that ATR mD (mD/mD) tumors contained the truncated ATR 
transcript of the appropriate size (Figure 2B, bottom left panel) while also containing the 
WT transcript. Additional studies verified that mRNA corresponding to the floxed form of 
ATR was expressed in melanoma tumors (Figure 2B, bottom right panel). In order to verify 
that ATR mt melanomas had defects in cell cycle checkpoints, ATRmD/mD and ATR+/+ 
tumors were lysed, and subjected to western blotting with p-Chk1(S345) Ab. ATRmD/mD 
tumor cells exhibited decreased phosphorylation of CHK1 (Figure 2C), indicating that these 
tumors lacked normal cell cycle checkpoints. ATRmD/mD tumors also had less expression of 
ATR but no change in the expression of ATM (Figure 2C) even though the ATR flox allele 
migrates at the same size of the WT allele (Figure S2C). Taken together, these findings 
verify that the ATRmD/mD tumors had ATR singaling defects.
To examine whether ATR signaling influenced tumor progression, Tyrosinase::CreERT2; 
BrafCA/+; Ptenfl/+; Atrfl/+ or Atrfl/fl mice were generated and tumor formation was induced 
by topical administration of 4-OHT. PTEN+/− tumors were specifically selected for these 
experiments as these tumors develop more slowly, making it easier to identify an effect of 
ATR on tumor growth. BRAFV600E PTEN+/− ATRmD/+ tumors grew larger than BRAFV600E 
PTEN+/− ATR+/+ tumors (Figure 2D), ultimately resulting in the tumor growing so large that 
these mice had to be sacrificed prematurely for compassionate reasons (Figure 2E) (decrease 
in median survival of 14 days). While BRAFV600E PTEN+/− ATRmD/mD tumors grew to a 
larger size than ATR WT tumors (Figure 2D), the BRAFV600E PTEN+/− ATRmD/mD tumors 
did not reach a sufficient size that mice needed to be sacrificed sooner than mice carrying 
BRAFV600E PTEN+/− ATRmD/+ tumors (Figure 2E). These observations are consistent with 
other studies that have indicated that ATR can have differing effects on tumor growth 
dependent on gene dosage (Gilad et al., 2010).
Deletion of both copies of PTEN in mouse melanomas rapidly accelerates their growth, 
resulting in a high tumor burden that goes on to generate lung metastases (Dankort et al., 
2009). Deletion of one or both copies of the ATR kinase domain in BRAFV600E PTEN null 
melanocytes did not result in an increased burden of tumors (Figure 2F), consistent with the 
published observation that BRAFV600E PTEN null tumors develop and metastasize rapidly. 
BRAFV600E PTEN−/− ATRmD/mD tumors did, however, have a higher propensity to 
metastasize to the lung as compared to BRAFV600E PTEN−/− tumors (Figure 2G, S2D). 
Taken together, these studies suggest that ATR mutations influence both the growth and 
metastasis of BRAF mt melanomas.
ATR mt promote the growth of BRAF mt nevi
As ATR mts modulate both tumor growth and metastasis, we next sought to examine the role 
of ATR mt in the growth of nascent tumors and nevi. First, we examined mice 75 days after 
birth when tumors are first readily visible. Both BRAFV600E PTEN+/− ATRmD/+ tumors and 
BRAFV600E PTEN+/− ATRmD/mD tumors (Figure 3A) were larger in size as compared to 
BRAFV600E PTEN+/− ATR+/+ tumors after 75 days. Moreover, a greater number of tumors 
Chen et al. Page 5
Cell Rep. Author manuscript; available in PMC 2018 March 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
were observed per mouse in mice carrying ATRmD/+ tumors and ATRmD/mD tumors (Figure 
3A) when compared to ATR+/+ tumors. Tyrosinase::CreERT2;BrafCA/+ mice develop 
melanocytic nevi after 4-OHT administration that can progress to melanoma after a 
prolonged duration (Dhomen et al., 2009). To more accurately assess whether ATR 
deficiency affects tumor initiation, we generated Tyrosinase::CreERT2; BrafCA/+ Atrfl/fl mice 
and induced precancerous nevi formation using topical 4-OHT treatment. Initial experiments 
verified that Tyrosinase::CreERT2; BrafCA/+ Atrfl/fl and Tyrosinase::CreERT2; BrafCA/+ mice 
had no difference in overall survival, and validated that these mice had similar survival as 
WT mice as noted in earlier publications (Dankort et al., 2009) (Figure S2A, S2B). The 
number of nevi after tamoxifen topical administration in Tyrosinase::CreERT2; BrafCA/+ 
Atrfl/fl and Tyrosinase::CreERT2; BrafCA/+ mice was quantified visually and using 
multiphoton microscopy (MPM), a technique that utilizes only intrinsic fluorescent signals 
to generate a three-dimensional image of melanoma tumors (Balu et al., 2014). 
Tyrosinase::CreERT2; BrafCA/+ Atrfl/fl mice develop more nevi after 4-OHT treatment 
compared to Tyrosinase::CreERT2; BrafCA/+ mice (Figure 3B). By measuring the intrinsic 
fluorescent signals from melanin (red), keratin (green), and the second harmonic signals 
from collagen (blue) using MPM (Balu et al., 2014) (Figure 3C, Supplemental video 1–3), 
we were able to determine that the developing ATR mt nevi were larger in volume (Figure 
3D) and occupied a larger volume of the skin (Figure 3E). There were also a larger number 
of nevi in Tyrosinase::CreERT2; BrafCA/+ Atrfl/fl mice although this number was just below 
statistical significance (p=0.0503) (Figure 3F). Taken together, these studies indicated that 
ATR deficiency affects tumor initiation.
ATR mt Melanomas Accumulate More Mutations
To investigate how ATR mutations affected mutation accumulation, the genomes of 
BRAFV600E PTEN+/− ATRmD/mD and BRAFV600E PTEN+/− ATR+/+ mouse tumors were 
sequenced and compared. Initial studies identified single nucleotide variants (SNVs) present 
in BRAFV600E PTEN+/− ATRmD/mD and BRAFV600E PTEN+/− ATR+/+ tumors and 
determined that ATR mt tumors accumulated more SNVs (Supplemental data file 1-sheet 4 
and sheet 5). Comparison of the number of SNVs in these two tumors revealed that ATR mt 
tumors accumulated more single nucleotide variants (Figure 4A). ATR SNVs had no 
predilection for specific transitions or transversions (Figure 4B), and were randomly 
dispersed across the genome, including both coding and regulatory regions (Figure 4C). In 
contrast, there was not a drastic increase in the number of translocations in ATRmD/mD 
tumors (two inversions and one area of LOH was observed, data not shown), suggesting that 
the ATR mutation was not a complete loss of function, as has been described by others 
(Ruzankina et al., 2007), as it resulted in the accumulation of SNVs and not translocations as 
observed in ATR null cells (Chanoux et al., 2009). In addition, while ATR mt tumors 
accumulated more SNVs in chromosome 7 and 12 (Figure 4A), these SNVs were evenly 
distributed across the chromosome and did not localize to any particular hotspot (Figure S3), 
indicating that the altered growth properties of these tumors was unlikely to be driven by a 
specific mutation induced by ATR loss.
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ATR mt Tumors Generate a Pro-Inflammatory Microenvironment that Supports Tumor 
Growth
Initial studies revealed that ATR mt melanoma cells do not proliferate more rapidly, as the 
number of Ki67 positive cells in ATR WT and mt tumors was similar (data not shown), 
consistent with published studies indicating that ATR function is required for cellular 
replication (Brown and Baltimore, 2003). In order to better understand how ATR deletion 
promotes the growth of tumors as a whole, RNA was collected from BRAFV600E ATRmD/mD 
nevi and BRAFV600E ATR+/+ nevi and subjected to RNA-seq and differential expression 
analysis (Figure S4A, Supplemental data file 1-sheet 6). ATR mt nevi had decreased 
expression of jun and fos (Figure 5A), serum response factors whose expression positively 
correlates with cellular proliferation (Verde et al., 2007), indicating that these tumors were 
not more proliferative (Figure S4A). Notably, ATR mt nevi had decreased expression of 
SkinT genes (Figure 5A), a class of genes known as butyrophilins (Abeler-Dorner et al., 
2012) that promote T cell homing to epithelia (Barbee et al., 2011). ATR mt nevi also had 
decreased expression of CD4, a marker for T-cells and other immune cells (Figure 5A), 
indicating that ATR tumors downregulate T-cell homing mechanisms. Taken together, these 
studies suggested that ATR mt tumors do not proliferate more rapidly but instead promote 
tumor growth by modulating the immune response.
To better characterize the effect of ATR mt on the immune response, flow cytometry was 
utilized to quantify the number of infiltrating immune cells in ATR mt and ATR WT tumors. 
ATRmD/mD melanoma tumors had decreased numbers of infiltrating T-cells (CD3+, pan T 
cell marker) and increased numbers of infiltrating macrophages (F4/80+) and B cells (CD19, 
B cell marker) as compared to ATRmD/+ and ATR+/+ tumors (Figure 5B). Interestingly, 40% 
of the cells in ATRmD tumors were macrophages. Consistent with this observation, RNA-seq 
analysis of BRAFV600E PTEN+/− ATRmD/mD tumors and BRAFV600E PTEN+/− ATR+/+ 
tumors did indicate that genes involved in immune activation were preferentially expressed 
in ATR mt tumors (Figure S5A, S5B, Supplemental data file 1-sheet 7). 
Immunohistochemical studies revealed that ATR mt tumors had increased numbers of 
infiltrating macrophages (Figure S4B) and decreased number of infiltrating T cells (Figure 
S4C), further verifying the flow cytometry results. Unfortunately, it was difficult to measure 
an effect on B cells histologically, as very few infiltrating B cells were present in either 
specimen (Figure S4D).
Blood monocytes extravagate into target tissues where they differentiate into mature 
macrophages and polarize into diverse subsets depending on environmental challenge 
(Murray and Wynn, 2011). While macrophage polarization is exceedingly complex, 
simplified in vitro models suggest that macrophages can polarize into “M1” subsets which 
are involved in generating an anti-tumor immune response or “M2” polarized subsets which 
can exert anti-inflammatory and pro-tumorigenic properties (Galdiero et al., 2013). 
Macrophages are detected in genetically heterogeneous tumors (Bauer et al., 2011) and can 
promote melanoma invasion and metastasis (Wang et al., 2015). Gene expression studies 
revealed that ATRmD/mD tumors expressed high levels of “M2” macrophage markers (Arg1, 
CD206, PPARG) (Martinez and Gordon, 2014), consistent with the contention that these 
infiltrating cells had pro-tumorigenic properties. In contrast, ATRmD/mD tumors exhibited 
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the same level of expression of markers known to be associated with “M1” anti-tumor 
macrophages (iNOS, TNF-α, IL-6) (Martinez and Gordon, 2014) (Figure 5C, 
Supplementary Data File 1 Sheet5). Melanoma cells are known to avoid the immune 
response by activating the expression of PD-L1 (Tumeh et al., 2014). ATRmD/mD tumors 
expressed higher levels of PD-L1 and lower levels of PD-1 as compared to ATR+/+ tumors 
(Figure 5D, Supplemental data file 1-sheet 7), indicating that ATR deficient tumors also 
modulated the PD1 immune checkpoint as is observed in human melanomas.
Discussion
Interactions between melanoma cells and immune cells are critical in promoting tumor 
initiation, tumor angiotropism (Bald et al., 2014), and therapy resistance (Holzel et al., 
2013). Cancer cells express PD-L1 and CTLA4, which prevents the immune system from 
recognizing and destroying tumor cells (Munn and Bronte, 2015), and PD-1 and CTLA4 
blocking antibodies can activate the anti-tumor response, leading to tumor regression 
(Larkin et al., 2015; Yang, 2015). Existing mouse melanoma models either generate clonal 
tumors with little diversity or examine the immune response in syngeneic models that poorly 
mimic human disease (Merlino et al., 2013). The autochthonous mouse melanoma model 
established here has an intact immune system and generates tumors with mutations in tumor 
drivers, tumor suppressors, as well as defects in DNA repair. The observation that M2 
macrophages promote tumor growth in this model are consistent with clinical observations 
that melanomas with more tumor-infiltrating, M2-like macrophages have a poorer prognosis 
(Bronkhorst et al., 2011), and other observations that macrophages promote melanoma 
metastasis (Wang et al., 2015). Interestingly, ATR mosaic, p53 null mice also had an 
increased number of macrophages localized around the hair follicle (Ruzankina et al., 2009), 
indicating that ATR deletion modulates macrophage function. Tumors from ATR mt mice 
also overexpress PD-L1, similar to what has been observed in human melanoma tumors that 
respond to PD1 inhibitors (Tumeh et al., 2014). In addition, ATR mt tumors downregulate 
the expression of butyrophilins (Abeler-Dorner et al., 2012), which normally promote T cell 
homing to epithelia (Barbee et al., 2011).
Recent studies have highlighted that tumors that have a higher mutation load are more 
responsive to immunotherapies (Snyder et al., 2014; Van Allen et al., 2015). While some 
studies have suggested that this is the result of generating more tumor neo-antigens, it is 
currently unclear why a tumor that expresses a high load of neoantigens would be resistant 
to immunotherapy in the first place. The studies presented here identify mutations within 
tumor cells themselves that allow them to suppress the T cell immune response and recruit 
macrophages known to promote tumor growth. The mouse model described here is an ideal 
system to elucidate how melanoma tumors modulate the immune response in order to 
develop better immunotherapies.
Experimental Procedures
Mouse breeding, activation of Tyrosinase::CreERT2 transgene, and experimental endpoints
Atrflox, Tyrosinase::CreERT2, BrafCa, and Ptenlox4-5 mice were genotyped using established 
protocols. 3μl of a 25 mg/ml solution of 4-OHT (98% Z-isomer, Sigma-Aldrich, St. Louis, 
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MO, USA) in DMSO was applied to the right flank, back skin and tail of mice on postnatal 
days 2, 3 and 4. Institutional Animal Care and Use Committee (IACUC) of the University of 
California Irvine approved our study protocols. The decision to euthanize mice was 
determined by independent University Lab Animal Resource (ULAR) staffs that were 
blinded with respect to the mouse genotype. Mice were euthanized if the volume of their 
tumors exceeded 10% of total body volume, if tumors were significantly ulcerated, if mice 
were moribund, if they lost weight, if they were lethargic, or if they were unable to 
ambulate.
Multiphoton microscopy of mouse skin
Experimental mice were shave depilated at p50 (second telogen), euthanized, and 
immediately imaged ex-vivo (no labeling) with multiphoton microscopy (MPM) to capture 
the fluorescence signal from keratin and melanins and second harmonic generated (SHG) 
signal from collagen using LSM 510 NLO Zeiss system. Fluorescence and second harmonic 
generation was excited by femtosecond Titanium: Sapphire (Chameleon-Ultra, Coherent) 
laser at 900 nm. Emission was detected at 390–465 nm for SHG channel (blue), and 500–
550 nm (green) and 565–650 (red) fluorescence channels. Each animal was imaged at 8 to 
10 randomly chosen locations on depilated skin of the lower back. Stacks of optical sections 
of 636μmx636μm at different depths ranging from 0 to 240 μm (5 μm steps) were obtained 
to allow for 3-D volume reconstruction (LSM Image Browser, Carl Zeiss GMBH).
Cell Culture and UVB irradition
For details, see Supplemental Experimental Procedures.
Western blotting of cell lines and mouse tumors and antibodies
For details, see Supplemental Experimental Procedures.
Expression of ATR wt and mt constructs in A375 melanoma cells
pcDNA3-ATR WT expression construct was purchased form Addgene (plasmid #31611). 
The ATR mts were generated by site-specific mutagenesis. (Agilent Technologies, Santa 
Clara, CA). Plasmids were transfected into A375 cell line by Turbofect transfection reagent 
(Thermo Scientific, Waltham, MA). 48hrs after transfection, cells were selected by G418 
selection for 7days. Selected cells were either exposed to UV irradiation as indicated or 
subjected to immunoprecipitation followed by western blotting as indicated.
EdU labeling and flow cytometry
Cells were labeled with 10 μM Edu for 1h, then were irradiated with UVB (250J/m2). At 0hr 
or 6hr post-UV cells were fixed and stained with Click-iT Plus EdU Alexa Fluor 647 Flow 
Cytometry assay kit (Life technology, Grand Island, NY, USA) according to the 
manufacture’s protocol. Cells were subjected to Flow Cytometry with an Attune Acoustic 
Focusing Cytometer (Life technology, Grand Island, NY, USA) to analyze the EdU positive 
cells. The resulting data were analyzed using Acoustic Focusing Cytometer software (Life 
technology, Grand Island, NY, USA).
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RNA-Seq., Genomic DNA-Seq., and Tumor volume measurements
For details, see Supplemental Experimental Procedures.
CD3, CD19and F4/80 flow cytometry analysis
End stage of mouse tumors were obtained from BRAFV600E PTEN+/− ATRmD/mD, or 
BRAFV600E PTEN+/− ATR+/+. Tumors were surgically excised, washed with 70% ethanol 
and PBS. Tumors were minced with a scalpel and dissociated using a tumor dissociation kit 
(#130-096-730) and gentleMACs (Miltenyi Biotec, Auburn, CA) according to the 
manufacture’s protocol. Dissociated tumor cells were labeled by CD3 (17A2)-PE/Cy7, 
CD19(6D5)-APC and F4/80 (BM8)-APC/Cy7 (BioLegend, San Diego, CA). Cells were 
subjected to flow cytometry using an Attune Acoustic Focusing Cytometer (Life technology, 
Grand Island, NY) to analyze the CD3, CD19 and F4/80 positive cells. The resulting data 
were analyzed using Acoustic Focusing Cytometer software (Life technology, Grand Island, 
NY, USA).
RAW264.7 culture and cytokine stimulation. And mRNA preparation, reverse transcription, 
and real-time PCR
For details, see Supplemental Experimental Procedures.
Statistical analysis
Kaplan Meier survival curves were generated and significance was assessed using the log-
rank test, an unpaired t-test, or a two way ANOVA test. Volume of pigmented lesions from 
MPM images were measured manually on orthogonal projections to access length, width 
and depth of a nevus as it is outlined by a bright luminescence from melanin. Four animals 
per group (wt vs mD/mD) were imaged. Other data was analyzed by GraphPad Prism6 
statistical analysis software using an unpaired t-test or two way Anova test. Significances 
were as indicated.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
• Loss of function mutations in ATR are present in human melanoma tumors.
• ATR mutant nevi and melanomas grow larger than tumors that have 
functional ATR.
• ATR mutant tumors recruit pro-tumorigenic macrophages and block T cell 
recruitment.
• ATR mutations accelerate tumor growth by modulating the tumor 
microenvironment.
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Figure 1. Loss of function ATR mutations are present in human melanoma
(A) ATR mts have a defective DNA damage checkpoints. ATR WT melanoma cell 
cultures were irradiated with UVB followed by western blotting with the indicated 
antibodies (Ab) (left panel). Relative protein accumulation was measured by densitometry 
(see values) relative to a GAPDH loading control. (B) ATR mutations do not accelerate 
the rate of proliferation of ATR mt human tumor cells. ATR WT or mts cells were 
labeled with EdU and the fraction of proliferating cells was determined. The graph 
represents the results of three independent experiments and error bars correspond to SEM. * 
p<0.05, **p<0.01; ***p<0.005 (C) ATR mts cells are more sensitive to UV-induced cell 
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cycle arrest. ATR WT or mt cells were labeled with EdU for 1hr, irradiated with UVB, and 
the fraction of EdU+ cells was determined 0 and 6 hr post-UV as described. * p<0.05, 
**p<0.01 (D) Expression of ATR mts in A375 cells impaired the normal DNA damage 
response. A375 cells expressing either ATR FLAG tagged WT or mt constructs were lysed 
and immunoprecipitation with a FLAG antibody (M2) followed by western blotting with an 
ATR Ab to verify that each mt was expressed (left top panel). Total lysate from each culture 
expressing ATR WT or mt constructs was also immunoblotted with the indicated antibodies 
and relative accumulation of pChk1/Chk1 and pChk1/GAPDH was determined by 
densitometry. See also Figure S1 and Table S1A, B.
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Figure 2. ATR haploinsufficiency promotes the invasion and metastasis of BRAF mt melanomas 
in mice
(A) Mice carrying various conditional alleles of Braf (BrafCA) , Pten (Ptenlox4-5) and/or ATR 
(ATRflox) were crossed to Tyr::CreER mice with melanocyte-specific expression Cre 
recombinase (CreERT2). Activation of CreER by 4-OHT leads to melanocyte-specific 
conversion of BrafCA to BrafV600E, Pten to null alleles and ATRflox to ATRmD. (B) 
Schematic of the ATRflox region (Brown and Baltimore, 2003). The kinase domain-encoding 
exons (KD1 and KD2) and primer locations were indicated (top panel). RT-PCR results are 
shown in the bottom panel. ATRmD/mD tumors expressed the floxed transcript. (C) 
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ATRmD/mD melanoma cells have defects in ATR signaling. Lysates from mouse tumors 
were subjected to western blotting with the indicated specific antibodies. Relative 
densitometry values are shown below each blot. n.d. means non-detectable. (D) ATR 
haploinsufficiency promotes the growth of BRAFV600E PTEN+/− tumors. The mean 
tumor volume of ATR+/+, ATRmD/+, and ATRmD/mD tumors was 91.23+22.68 mm3 (n=28), 
428.6+57.95 mm3 (n=28) (p<0.0001), and 495.4+145.8 mm3 (n=27) (p=0.0074), 
respectively. Error bars represent SEM. Representative photographs are shown (top panel). 
(E) ATR haploinsufficiency accelerates the demise of mice harboring BRAFV600E 
PTEN+/− tumors. Kaplan Meier survival curves for mice harboring BRAFV600E PTEN+/− 
with ATR+/+, ATRmD/+, and ATRmD/mD tumors with median lifespan 109 days (n=20), 95 
days (n=25), and 97 days (n=11), respectively. (F) ATR haploinsufficiency does not 
accelerate the demise of mice harboring BRAFV600E PTEN−/− tumors. Kaplan Meier 
survival curves for mice harboring BRAFV600E PTEN−/− with ATR+/+, ATRmD/+, and 
ATRmD/mD tumors with median lifespan 39 days (n=13), 37 days (n=23), and 40.5 days 
(n=12), respectively. (G) ATR haploinsufficiency promotes the metastasis BRAFV600E 
PTEN−/− tumors. Mice bearing ATR+/+, ATRmD/+, and ATRmD/mD tumors averaged 
1.22+0.43 (n=9), 6.60+0.75 (n=15) and 7.00+0.62 (n=7) metastases per mouse lung 
(p<0.0001), respectively. Error bars represent SEM. See also Figure S2 and Table S2.
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Figure 3. ATR mt promotes the growth of BRAF mt nevi and melanomas
(A) ATR mt promotes the growth of developing melanoma tumors. Tumors were 
induced in BrafCA/+ Ptenfl/+ Atrfl/+ or BrafCA/+ Ptenfl/+ Atrfl/fl mice and the size (bottom left 
panel) and number of tumors per mouse (bottom right panel) was determined after 75 days. 
Mice bearing ATR+/+ tumors had an average of 1.38+0.42 (n=8) tumors per mouse with a 
mean volume of 6.06+2.31 mm3 (n=13). Mice bearing ATRmD/+ tumors had an average of 
3.9 +0.64 (n=10) tumors per mouse (p=0.0067) with a mean volume of volume of 
70.69+19.42 mm3 (n=19), (p<0.0001). ATRmD/mD mice had an average of 3.33+0.88 (n=4), 
(p=0.048) with a mean volume of 74.69+22.77 mm3 (n=10), (p<0.0001). Error bars 
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represent SEM. (B) ATR mutation promotes the growth of BRAF mt nevi. Nevi were 
induced in BrafCA/+ Atr+/+ and BrafCA/+ Atrfl/fl mice and visualized 50 days after induction 
on the underside of the skin by standard photography. Mice bearing ATRmD/mD and ATR+/+ 
nevi had an average of 259.8 +11.72 (n=4), and 74.75+27.69 (n=4) nevi per mouse, 
respectively. (p=0.0008). Error bars represent SEM. (C) ATR mt and ATR wt nevi 
visualized by label-free multiphoton microscopy of the mouse skin ex-vivo. MPM 
images from mice were obtained as described in methods, and a representative image from 
each genotype is shown. Top row (left to right): 3-D projections for normal skin, ATR wt 
and ATRmD/mD. Bottom row: orthogonal projection from the stacks of images. Colored lines 
indicate positions being displayed as xy (blue), xz (red) and yz (green) planes. FOV is 
636μm x 636μm Cyan: SHG of collagen; Green: fluorescence of keratin; Yellow and Red – 
fluorescence of melanin. (D) ATR mt nevi are larger than ATR wt nevi. Average volume 
of melanocytic nevi within the upper 50 μm of the skin was measured (μm3) from 3-D skin 
reconstructions. (E) ATR mt nevi occupy a greater volume of the skin as compared to 
ATR wt nevi. Percentage of a volume occupied by pigmented lesions within the upper 50 
μm of the skin compared to the total probed volume is reported and error bars represent S.D. 
(F) ATR mt promote the formation of BRAF mt nevi. Individual lesions were counted 
manually for all acquired stacks of images to the depth of 240 μm and then normalized to the 
volume of 10 stacks per each animal. A graph obtained from analyzing 5 mice in each group 
is shown.
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Figure 4. ATR mt Leads to the Generation of a Genetically Heterogeneous Tumor
(A) ATR mt leads to the increased accumulation of single nucleotide variants in 
melanoma tumors. SNVs that were unique to ATRmD/mD tumors (not present in ATR+/+ 
tumors) were identified as described in methods. The number of ATR-dependent SNVs (as 
defined in the methods section) at each chromosomal location is reported in the graph. mD 
denotes ATR mt tumor and WT denotes ATR WT tumors. (B) ATR mt does not lead to the 
increased accumulation of specific transitions or transversions. The number of specific 
transitions and transversions that were unique to ATRmD/mD tumors was determined, and the 
relative proportion of each transition/transversion (proportion of total) is indicated. (C) 
Mutation frequencies in ATR mt Tumors. The frequencies of single nucleotide variants in 
ATR mt tumors were determined as described in methods. The number of coding and non-
coding variants as well as the number of synonymous and non-synonymous variants was 
reported for each ATR mt tumor (mD1-mD4). See also Figure S3.
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Figure 5. ATR mt tumors contain a greater number of infiltrating macrophages
(A) ATR mt nevi modulate the immune response. RNA-sequencing and gene expression 
analysis was performed on ATR WT and ATR mt mouse nevi as described. Differentially 
expressed genes that regulate proliferation and the immune response identified in the dataset 
are shown here, while a larger heatmap (Figure S5A) and dataset is provided in the 
supplement (Supplemental data file 1 sheet3). Hierarchical clustering of RNA-seq 
normalized read counts obtained from EdgeR ranging from less frequently expressed (dark 
blue) to highly (dark red) genes is shown. (B) ATR mt tumors recruit macrophages to 
create a pro-inflammatory tumor microenvironment. ATR wt and mt tumor cells were 
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labeled by CD3 (T cell marker), CD19 (B cell marker) and F4/80 (macrophage marker) 
antibodies and sorted by flow cytometry as described in the supplement. * p<0.05, 
***p<0.001. 5 tumors were analyzed per group. Error bars represent SEM. (C) ATR mt 
tumors are enriched in M2 like macrophages. RNA samples from ATR wt or mt tumors 
were subjected to RT-qPCR. The top panel represents of M1 macrophage expression of 
iNOS, TNFα and IL-6. The bottom panel represents of M2 macrophage expression of 
ARG1, CD206 and PPARG. (D) ATR mt tumors express more PD-L1. RNA samples from 
ATR wt or ATR mt tumors were subjected to RT-qPCR using primers specific for PD-1 or 
PD-L1. ***p<0.001, ****p<0.0001, error bars represent SEM. See also Figure S4, S5, S6 
and Table S2
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